Exclusion Criteria:~* The patient satisfies the NINDS-AIREN criteria for probable vascular dementia.~* A known
exaggerated pharmacological sensitivity or allergy to NSAID's.~* History of peptic ulceration, gastric surgery
or gastrointestinal bleeding.~* Current diagnosis of active peptic ulceration.~* Current diagnosis of severe
and unstable cardiovascular disease.~* Current diagnosis of renal failure.~* Advanced, severe and unstable
disease of any type, other than Alzheimer's disease, that may interfere with primary and secondary variable
evaluations, including a medical condition which should be expected to progress, recur, or change to such an
extent that it may bias the assessment of the clinical or mental status of the patient to a significant degree
or put the patient at special risk.~* Intake of any of the following concomitant medications: salicylates,
coumarin derivatives, ACE-inhibitors, loop diuretics.~* Intake of any of the following concomitant medications
more than two months immediately prior or during the study: NSAID's, systemic corticosteroids.~* Intake of any
of the following concomitant medications with a possible effect on cognition: estrogen, deprenyl, vitamin E,
neuroleptics, anticholinergics. Patients using stable doses of cholinesterase inhibitors were eligible, with
the provision that the dose should not be changed during the study. Cholinesterase inhibitors could not be
initiated during the study.~* Excessive use of alcohol (more than 5 units per day)~* The patient is, either
alone or with the aid of a caregiver, not able to reliably take the medication.
